Arbutus Biopharma Corp Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
Arbutus Biopharma Corp (ABUS) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax of $60.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $60.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $23.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $4.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2026-06-30 | $60.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $23.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
| 2025-09-30 | $4.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $11.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $6.00K 10-K · filed 2026-03-23 |
| 2021-12-31 | $150.00K 10-K · filed 2022-03-03 |
| 2021-06-30 | $19.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.00K 10-K · filed 2022-03-03 |
| 2019-12-31 | $4.00K 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |